# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-26-186923
Filing Date
2026-04-28
Accepted
2026-04-28 16:05:11
Documents
14
Period of Report
2026-04-27

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | bolt-20260424.htm iXBRL | DEF 14A | 981304
2 | GRAPHIC | img117169523_0.jpg | GRAPHIC | 16109
3 | GRAPHIC | img117169523_1.jpg | GRAPHIC | 329667
4 | GRAPHIC | img117169523_2.jpg | GRAPHIC | 147240
| Complete submission text file | 0001193125-26-186923.txt |  | 2511163

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | bolt-20260424.xsd | EX-101.SCH | 8289
17 | EXTRACTED XBRL INSTANCE DOCUMENT | bolt-20260424_htm.xml | XML | 3229

Mailing Address 900 CHESAPEAKE DRIVE REDWOOD CITY CA 94063
Business Address 900 CHESAPEAKE DRIVE REDWOOD CITY CA 94063 650-665-9295
Bolt Biotherapeutics, Inc. (Filer) CIK: 0001641281 (see all company filings)

EIN.: 472804636 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39988 | Film No.: 26907566
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)